PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan, announced that on Thursday, March 26, it signed an investment agreement for a new manufacturing facility in Toa Baja, Puerto Rico. The signing ceremony marks an important milestone in the company’s strategy to establish a dual-site manufacturing network in Taiwan and the United States, strengthening global supply chain resilience and supporting long-term growth.

The signing ceremony was attended by Puerto Rico Governor Jenniffer González Colón, Secretary of Economic Development and Commerce Sebastián Negrón Reichard, U.S. Department of Commerce Director for Puerto Rico and the U.S. Virgin Islands Jose Burgos, Director General of the Taipei Economic and Cultural Office (TECO) in Miami Chi Yu Chou, Director of Economic Development of the Municipality of Toa Baja James Ramos, and CEO of Invest Puerto Rico Ella Woger-Nieves, among other distinguished officials. Their participation underscores the strong bilateral collaboration between Taiwan and the United States in advancing life sciences manufacturing and innovation.

Chairperson Dr. Ching-Leou Teng opened the ceremony with a clear statement of intent: "This is not just a closing — it is the start of a long-term partnership and a clear demonstration of our commitment to patients."

“This investment reaffirms Puerto Rico’s position as a reliable and competitive U.S. jurisdiction for advanced biopharmaceutical manufacturing. We continue to attract projects that strengthen our economy, create specialized jobs, and contribute to the resilience of the United States’ supply of critical medicines,” said Governor Jenniffer González Colón.

Director General Chi Yu Chou of TECO Miami stated that PharmaEssentia's investment in Puerto Rico reflects the strengthening economic ties between Taiwan and the United States. “The company's dual production strategy embodies the symbiotic partnership between the two sides, as emphasized by Foreign Minister Lin Chia-lung. This project demonstrates the breadth and resilience of Taiwan's industries, extending beyond AI and semiconductors into biotechnology and healthcare. It also underscores the potential for deeper bilateral economic cooperation and the continued global competitiveness of Taiwanese enterprises in high-value sectors.”

The Puerto Rico facility is designed to the same high-quality standards of PharmaEssentia's existing manufacturing site in Taichung, Taiwan, while optimizing production efficiency and diversifying manufacturing risk. Personnel from the Puerto Rico facility will complete intensive training at the Taichung site to support knowledge transfer and operational readiness. The company is planning for the facility to begin operations in 2027 and is committed to engaging with regulators to obtain all necessary approvals.

“Expanding manufacturing capacity outside Taiwan is a core strategic priority for PharmaEssentia,” said Dr. Ko-Chung Lin, Founder and Chief Executive Officer. “We are proud to establish U.S.-based manufacturing, with Puerto Rico serving as a key hub to support the U.S. market and our commitment to patients worldwide – including those benefiting from BESREMi® (ropeginterferon alfa-2b-njft).”